Systematic Review: Management options for primary sclerosing cholangitis and variant forms; IgG4-associated cholangitis and overlap with autoimmune hepatitis

Emma L Culver, Roger Chapman

► To cite this version:

Emma L Culver, Roger Chapman. Systematic Review: Management options for primary sclerosing cholangitis and variant forms; IgG4-associated cholangitis and overlap with autoimmune hepatitis. *Alimentary Pharmacology and Therapeutics*, 2011, 33 (12), pp.1273. 10.1111/j.1365-2036.2011.04658.x . hal-00633214

HAL Id: hal-00633214

<https://hal.science/hal-00633214>

Submitted on 18 Oct 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Systematic Review: Management options for primary sclerosing cholangitis and variant forms; IgG4-associated cholangitis and overlap with autoimmune hepatitis

Journal:	<i>Alimentary Pharmacology & Therapeutics</i>
Manuscript ID:	APT-0990-2010.R1
Wiley - Manuscript type:	Systematic Review
Date Submitted by the Author:	23-Mar-2011
Complete List of Authors:	Culver, Emma; John Radcliffe Hospital Oxford, Gastroenterology Chapman, Roger; John Radcliffe Hospital Oxford
Keywords:	Primary sclerosing cholangitis < Hepatology, Cholangiocarcinoma < Hepatology, Inflammatory bowel disease < Disease-based, Liver transplantation < Hepatology, Autoimmune liver disease < Hepatology, Cholestatic liver disease < Hepatology

Title Page

Systematic Review: Management options for primary sclerosing cholangitis and its variant forms; IgG4-associated cholangitis and overlap with autoimmune hepatitis

E L Culver & R W Chapman

Author details;

Dr Emma L Culver,

Gastroenterology Registrar

John Radcliffe Hospital, Oxford, UK

Dr Roger W Chapman,

Consultant Hepatologist*

John Radcliffe Hospital, Oxford, UK

Contact email: roger.chapman.ox.ac.uk

***corresponding author**

Keywords;

Primary sclerosing cholangitis, IgG4-associated cholangitis, overlap with autoimmune hepatitis, ursodeoxycholic acid, cholangiocarcinoma, inflammatory bowel disease, liver transplantation

ABSTRACT

Background: Primary sclerosing cholangitis (PSC) remains a challenging disease to manage. The main goals are prevention of disease progression and reduction of the increased cancer risk

Aims: To review the management strategies for PSC and its variant forms based on published studies.

Methods: Publications were identified using Pubmed, Medline and Ovid search engines.

Results: Distinguishing PSC from variants such as IgG4-associated cholangitis and overlap with autoimmune hepatitis is essential to guide treatment decisions. There is no proven efficacious medical treatment for PSC. Ursodeoxycholic acid has been disappointing in low and moderate doses, and potentially dangerous in higher doses, although its role and optimal dose in chemoprevention requires investigation. The novel bile acid 24-norursodeoxycholic acid has shown promise in mouse models; human trials are in progress.

Dominant strictures are optimally managed by dilatation and stenting to relieve obstructive complications, although exclusion of biliary malignancy is essential. Liver transplantation is the only proven therapy for those with advanced disease.

Cholangiocarcinoma remains the most unpredictable and feared complication. In highly selected groups, neo-adjuvant chemoradiation with liver transplantation seems

promising but requires further validation. Screening for inflammatory bowel disease and surveillance for colorectal carcinoma should not be overlooked.

Conclusion: The effective management ofPSC and its variantsis hindered by uncertainties regarding pathogenesis of disease and factors responsible for its progression. Genome studies may help to identify further targets for drug therapy and factors leading to malignant transformation.

For Peer Review

INTRODUCTION

Primary sclerosing cholangitis (PSC) is a chronic progressive disorder characterised by inflammation, fibrosis and stricturing of intrahepatic and extrahepatic bile ducts, ultimately leading to liver cirrhosis. The aetiology is poorly understood; an immune-mediated basis is suggested by lymphocytic portal tract infiltration and association with autoantibodies, human leukocyte antigen (HLA) haplotypes (HLA B8 DR3 and DQ2), other autoimmune diseases and inflammatory bowel disease¹. It is not a classical autoimmune disease however, with a male predominance, ratio of 2 to 1, and a poor response to immunosuppressive agents. There is strong evidence for genetic susceptibility from genome wide association analysis². The current management of PSC is limited by uncertainties regarding its pathogenesis and factors responsible for its progression. In particular, the use of ursodeoxycholic acid in PSC has received much attention in light of recent studies, which will be discussed in this review, and the recognition of variant forms requiring careful diagnosis and individualised management.

METHODS

Publications were identified using pubmed, medline and ovid search engines to include controlled and randomized clinical trials, meta-analysis, practice guidelines, reviews and case reports in English language from January 1980 to January 2011 inclusive. Search words were primary sclerosing cholangitis (PSC), small duct PSC, IgG4-associated sclerosing cholangitis, autoimmune hepatitis overlap, ursodeoxycholic acid, cirrhosis and liver transplantation, inflammatory bowel disease, cholangiocarcinoma, and colorectal carcinoma. 2710 publications were identified, of which 974 met the search inclusion criteria. Abstracts with no full article available and any duplicate studies were further excluded from analysis.

DIAGNOSIS

The clinical presentation of PSC is variable; about 50% are symptomatic at first presentation with abdominal pain, pruritis, fatigue, weight loss and fevers³. Portal hypertension and liver cirrhosis may manifest later in the disease. Asymptomatic patients are often identified after investigation of persistent cholestatic liver function or after a cholangiogram shows characteristic bile duct stricturing and segmental dilatation, once secondary sclerosing cholangitis and other causes of cholestasis are excluded⁴. Laboratory investigation often reveals cholestatic liver biochemistry; an elevated alkaline phosphatase is the most common finding. Liver tests may be normal in 8.5% of cases and may fluctuate during the disease course³. Elevations in immunoglobulin G have been described in up to 60% of patients⁵. A wide range of non-specific autoantibodies can be detected in the serum; atypical perinuclear neutrophil cytoplasmic antibody has the strongest association with PSC, present in 33-88% of cases⁶⁻⁷.

The diagnosis of PSC is usually established on the basis of a cholangiogram, demonstrating abnormal beading, irregularity and narrowing of the bile ducts. Magnetic resonance cholangiogram (MRC) is considered the gold standard as it is non-invasive, uses non-ionizing radiation and can delineate distal bile duct anatomy in the presence of proximal obstruction⁸. In a meta-analysis of 456 subjects, MRC had a high sensitivity and specificity for detection of PSC, 0.86 and 0.94, respectively with positive and negative predictive ratios of 15.3 and 0.15, respectively⁹. If MRC images are suboptimal, endoscopic retrograde cholangiopancreatography (ERCP) can be used, although it is usually reserved for sampling in the presence of a dominant stricture and for intervention to relieve biliary obstruction. Liver biopsy may show histological features diagnostic of PSC but only in one third of patients, and findings

are often non-specific in early disease due to the patchy, focal nature of the disease¹⁰. In the presence of an abnormal cholangiogram, liver biopsy is considered to yield little extra information, except in diagnosing suspected variants of PSC¹¹..

VARIANTS OF PSC

Small-duct PSC

This refers to a subgroup of patients who have clinical, biochemical and histological features compatible with PSC, but a normal cholangiogram. In the largest natural history study of 83 patients with small-duct PSC, only 22.9% of patients progressed to large-duct PSC over a median of 7.4 years (range 5.1-14 years)¹². The course of small-duct PSC was less aggressive, with significantly longer transplantation-free survival, 13 years versus 10 years (95% CI 1.82-5.06; $P < .0001$), confirming earlier smaller studies¹³⁻¹⁵. Liver-related mortality, liver transplantation and post transplantation recurrence have been reported in small-duct PSC; however cholangiocarcinoma has only been described in those patients that progress to large-duct PSC¹².

Diagnostic criteria for small-duct PSC remains to be defined, although a high-quality cholangiogram is mandatory to exclude PSC with isolated intra-hepatic distribution, and mutation analysis may be necessary to exclude other cholangiopathies such as ABCB4 deficiency causing compatible histological features¹⁶. Inflammatory bowel disease has been described in 50–88% of patients with small-duct PSC¹⁴⁻¹⁵. In patients with IBD and cholestatic liver enzymes, a normal high quality MRC scan should prompt liver biopsy and histological analysis for evidence of small-duct PSC.

Management of patients with small-duct PSC is not well defined. In a longitudinal cohort study of 42 patients with small-duct PSC followed up for up to 24.9 years, the presence of IBD resulted in earlier diagnosis, but had no impact on long-term prognosis. UDCA therapy in both groups improved liver biochemistry over an average of 40 months ($p<0.001$), but had no effect on delaying disease progression (RR 0.95, CI 0.38-2.36)¹⁷. Liver transplantation is indicated for advanced liver disease, with a risk of recurrence in the transplanted liver. There are currently no agreed guidelines for surveillance of patients with small-duct PSC for the development of large-duct PSC.

PSC with overlap features of autoimmune hepatitis

This is an ill-defined immune-mediated disorder with histological features of autoimmune hepatitis (AIH) and cholangiographic findings typical of PSC. It has been described predominantly in children, adolescents and young adults¹⁸⁻¹⁹. The diagnostic criteria are not well defined. A retrospective diagnosis of ‘PSC-AIH overlap syndrome’ was established in 8% of 113 PSC patients from The Netherlands and 1.4% of 211 PSC patients from the United States, using the modified AIH score²⁰⁻²¹. Prospective analysis revealed an overlap syndrome in 17% of a cohort of 41 PSC patients from Italy, defined by a revised AIH score of over 15, anti-nuclear antibody or anti-smooth muscle antibody titre of at least 1:40, and characteristic histological abnormalities²². Prevalence of AIH in adults with sclerosing cholangitis has been reported to vary from 1.7%, when identified prospectively by MRC and liver biopsy and not including intrahepatic duct abnormalities associated with fibrosis score on biopsy, to 10% when identified prospectively on MRC and associated with a younger

age, high ALP at baseline and bilirubin at the time of scan and lobular activity on initial biopsy²³⁻²⁴.

The development of PSC and AIH may be sequential in occurrence, thus in patients with PSC an elevation in serum transaminases should prompt a search for AIH, and patients with AIH, cholestasis or resistance to immunosuppressive therapy should raise suspicion of PSC²⁵. UDCA and immunosuppressive therapy are often prescribed in combination in patients with PSC–AIH overlap syndrome, although there are no controlled studies evaluating this approach. Retrospective studies have suggested a benefit of corticosteroids in adult patients with PSC and AIH overlap features²⁶. In a prospective Italian study, overlap patients treated with UDCA (15–20 mg/kg/day), prednisolone (0.5 mg/kg/day, tapered to 10–15 mg/d) and azathioprine (50–75 mg), showed a good biochemical response²². PSC–AIH overlap syndrome has a better prognosis than PSC, as predicted by the Mayo score, but poorer outcome than AIH^{19,22}. Liver transplantation is indicated for advanced disease.

IgG4-associated cholangitis

Immunoglobulin G subclass 4-associated cholangitis (IAC) is a biliary disease of unknown immunopathogenesis, with cholangiographic features indistinguishable from PSC, but distinct histological findings and a dramatic response to corticosteroids²⁷. In the largest cohort of 53 IAC patients from the Mayo clinic, median age at diagnosis was 60 years in a predominantly male patient group (85%), frequently presenting with obstructive jaundice²⁸. IBD is less frequently associated with IAC than PSC, described predominantly in case reports and small series, although IgG4 positive plasma cells have been detected in colonic specimens in

patients with autoimmune pancreatitis and IgG4-related colitis may mimic IBD²⁹⁻³⁰.

Diagnostic criteria have been proposed for IAC based on characteristic histological and cholangiographic findings, elevations in serum IgG4, systemic organ involvement and response to corticosteroids²⁸. These are still to be cross-validated in an independent cohort of patients.

It is important to differentiate IAC from PSC; elevated levels of serum IgG4 were found in 9% of 127 patients previously diagnosed with PSC in one series from the Mayo Clinic. Patients with elevated IgG4 had more severe biochemical parameters, higher Mayo risk score and a shorter time to transplantation suggesting a more severe disease course³¹. Patients with elevated IgG4 had more aggressive course pre and post transplantation³². The relevance of these observations remains to be determined, although in the meantime cohorts of PSC patients should be scrutinised to detect patients with IAC, given the different management strategies and possible outcome. Dominant strictures of IAC may also mimic hilar cholangiocarcinoma (CCA), which must be rigorously excluded prior to initiation of treatment³³. The importance of intrahepatic cholestasis and elevated serum IgG4, in the context of a normal cholangiogram, is still to be elucidated.

Corticosteroids result in resolution of jaundice, improved liver biochemistry, a reduction of serum IgG4 levels and reversal of strictures on cholangiogram in patients with IAC²⁸. Relapse has been documented in 40% of patients after completing an 11 week course of steroids in a retrospective study from the Mayo group; post-hoc analysis revealing strictures of the proximal extrahepatic and intrahepatic bile ducts were associated with a higher risk of relapse compared with those with strictures of

the distal ducts, the extent of disease perhaps affecting long-term response²⁸. Similarly, corticosteroids can be used in the management of IgG4-associated autoimmune hepatitis variant, which responds dramatically to steroids in the initial and maintenance phase of treatment with less relapse reported in a small retrospective study, although further studies are needed to confirm this³⁴. Azathioprine at doses up to 2 mg/kg/day should be considered in those with proximal and intrahepatic stenoses and those that relapse during and/or after corticosteroid therapy. Rituximab, a monoclonal antibody directed against CD20 antigen on B lymphocytes, has been used successfully in a patient unresponsive to other immunosuppressive agents³⁵. Natural history and prognosis has not been adequately defined.

MANAGEMENT OF PSC

The main goals of therapy are retardation and reversal of the disease process and management of progressive disease and its complications. Prognostic models have limited value in the individual patient because of disease variability and the presence of confounding factors, such as biliary sludge and stones, main duct strictures, and CCA. The Mayo risk score provides the most valid survival information in early PSC in patient cohorts³⁶⁻³⁷. Although the course is variable, PSC is generally progressive and leads to biliary cirrhosis. The 10-year survival was approximately 65% in a population study from the United States³⁸. A median transplantation-free survival of 18 years was reported in a Dutch population³⁹. Liver failure and CCA are the two major complications that affect survival, malignancy becoming the most important cause of death over the last decade⁴⁰.

SPECIFIC MEDICAL THERAPY

The search for an effective medical treatment for PSC has been hindered by uncertainties regarding the pathogenesis of disease and factors responsible for its progression. There is no medical therapy to date that conclusively alters the natural history of disease. Ursodeoxycholic acid (UDCA), a hydrophilic dihydroxy bile acid, is the most extensively studied medical therapy for PSC. It is believed to exert a number of beneficial effects in chronic cholestatic conditions, including direct and indirect cytoprotection, stimulation of hepatobiliary secretion, immunomodulation and protection of hepatocytes from bile-induced apoptosis⁴¹. The relative importance of each in alleviating cholestasis remains unclear. UDCA may also have a chemoprotective effect; inhibiting proliferation of tumour cell lines in vitro⁴².

UDCA in cholestasis and disease progression

A number of trials have attempted to address the clinical efficacy of UDCA in the context of PSC, summarised in **Table 1**. Early pilot studies of UDCA, in doses ranging from 10 to 15 mg/kg/day, demonstrated biochemical and in some, histological improvement⁴³⁻⁴⁶. A larger double-blind placebo-controlled study of UDCA 13-15mg/kg/day in 105 patients with PSC showed an improvement in liver biochemistry, but no improvement in symptoms, histological progression, development of portal hypertension or liver transplantation after 2 to 5 years of therapy⁴⁷. Further analysis, suggested a trend towards increased transplant-free survival in the treated group⁴⁸.

Higher doses of UDCA, 20 mg/kg/day, were evaluated in a double-blind placebo-controlled trial of 26 patients, showing improvements in liver biochemistry, cholangiographic appearance and histological progression, but no effect on survival after 2 years of therapy⁴⁹. A larger multi-centre randomised study of UDCA at 17-23

mg/kg/day in 219 patients demonstrated a non-significant trend towards increased survival in the UDCA treated group compared to placebo over 5 years, although it was insufficiently powered to achieve statistical significance and biochemical response was poor suggesting an issue with drug compliance⁵⁰.

A randomised dose-ranging trial in 30 PSC patients was conducted to look at outcomes of higher doses of UDCA over 2 years; the low dose (10 mg/kg/day) and the standard dose (20 mg/kg/day) showed a trend towards improved survival, and the high dose (30 mg/kg/d) significantly improved projected survival compared with the Mayo risk score⁵¹. However, a multi-centre placebo-controlled randomised study using high dose UDCA, 28-30 mg/kg/day in 150 patients over 5 years was discontinued early as the patients randomised to UDCA, despite having improvement in liver biochemistry, were significantly more likely to reach the primary outcome of death, liver transplantation or development of varices compared with the placebo group, especially in more advanced disease⁵². The reason for this remains unclear; the authors postulating that high-dose UDCA may cause direct hepatocyte necrosis in patients with advanced PSC with downstream biliary obstruction due to strictures, or that high-dose UDCA may lead to increased levels of hepatotoxic lithocholic acid, produced in the right colon⁵³⁻⁵⁴. A subsequent analysis of the serum bile acid profile of 56 patients in the high dose UDCA group has so far demonstrated significant expansion of the total serum bile acid pool, including lithocholic acid compared to the placebo group ($P = 0.001$)⁵⁵. Further analysis of this data is awaited.

To date, many studies have enrolled patients with advanced stage disease; the role of UDCA much earlier in the disease process may have a different impact but has not been fully assessed.

UDCA in chemoprevention

Colorectal carcinoma in patients with PSC and IBD

Retrospective studies support a role for UDCA in reducing the risk of colorectal carcinoma (CRC) in patients with PSC and UC. A cross-sectional study of 59 PSC patients with UC undergoing colonoscopic surveillance found a significantly reduced prevalence of colonic dysplasia in patients taking UDCA (OR 0.18, 95% CI 0.05-0.61), although there was an exceptionally high rate of dysplasia in the control group⁵⁶. In a follow-up of 52 patients with PSC and UC, who participated in a randomised placebo-controlled trial of UDCA, over 355 patient-years, the UDCA-treated patients had a significant reduction in the relative risk of developing CRC or dysplasia (RR 0.26, 95% CI 0.06–0.92, p = 0.003)⁵⁷. A historical cohort study, comparing 28 patients with PSC and UC treated with UDCA with 92 patients not treated with UDCA, reported a trend towards a lower risk of colonic dysplasia and neoplasia and a significantly lower mortality in those treated with UDCA⁵⁸. However, there have been no prospective controlled trials investigating the role of UDCA in chemoprevention, and the most effective dose is still to be elucidated.

Cholangiocarcinoma in patients with PSC

Observational studies provide limited evidence for a beneficial effect of UDCA on the risk of developing CCA. In a single controlled study of 150 patients with PSC treated with UDCA over a median of 6.4 years, a lower annual incidence rate of CCA

(3.3%) was reported in PSC patients treated with UDCA, this rate decreasing with length of treatment (0.59 in year 0 to 2.5, 0.58 in years 2.5 to 8.5, none in years 8.5 to 18)⁵⁹. In a study of 255 PSC patients listed for liver transplantation over a period of 11 years, the absence of UDCA was an independent risk factor for the development of hepatobiliary malignancy⁶⁰. However, two randomized placebo-controlled UDCA trials with 219 and 150 PSC patients, did not observe a difference in CCA development in the UDCA and placebo-treated groups^{50,52}. Thus, there is insufficient evidence to support the use of UDCA for chemoprevention of CCA at this time.

24-norursodeoxycholic acid

An alternative novel bile acid, 24-norursodeoxycholic acid, an inhibitor in the formation of toxic bile, has been shown to have antifibrotic, anti-inflammatory and antiproliferative effects in a knockout multi-drug resistance protein 2-null (Mdr2-/-) mouse model of cholangitis and biliary fibrosis, reversing sclerosing cholangitis within 4 weeks of treatment⁶¹⁻⁶². Human studies are currently in progress.

Other therapies (summarised in Tables 2-4)

Studies of glucocorticoids and immunosuppressive agents have been disappointing, none demonstrating convincing evidence of benefit and a few associated with significant side effects⁶³. Antifibrotic agents, anti-TNF monoclonal antibodies, and other agents with TNF-alpha antagonising effects have been evaluated with no overall benefit. Pilot studies of combination therapy have been encouraging but inconclusive, conducted in small number of patients treated for short periods of time, with end points focussing on improvements in biochemistry and Mayo risk score. There is no data evaluating survival or time to liver transplantation. The presence of PSC variants

in some of the patient groups may overestimate benefits. Trials evaluating antibiotics such as metronidazole and minocycline have been promising but inconclusive.

BILIARY COMPLICATIONS

PSC can be complicated by the formation of dominant strictures, recurrent bacterial cholangitis, development of gallstones and gallbladder polyps, and the increased risk of carcinoma of the biliary system and gallbladder⁶⁴.

Dominant strictures

A dominant stricture has been defined as ‘a stenosis with a diameter of less than or equal to 1.5mm in the common bile duct or of less than or equal to 1mm in the right and/or left hepatic duct’⁶⁴. The majority of patients with advanced PSC develop dominant stenoses of major bile ducts; in one of the largest studies of 125 patients with PSC, 45% had a dominant stricture of the common bile duct and/or right or left hepatic ducts⁶⁵. Furthermore, patients who do not have a stricture at diagnosis may develop one over time; a study of 106 PSC patients reported 40% developed a dominant stricture over five year follow-up⁶⁶. Dominant strictures are associated with a reduced transplant-free survival; in one prospective study transplantation-free survival at 18 years was 25% compared with 73% in those with or without dominant stenoses, respectively (p=0.011)⁶⁷.

Given their relative frequency, stenotic lesions are more likely to be benign than malignant. However, the presence of a dominant stricture should always raise the suspicion of CCA, which may develop in 10-15% of patients with PSC⁶⁸. Endoscopic

brushings and/or biopsy and further imaging of the biliary system are usually required to differentiate the two.

Interventions to decompress the biliary tree aim to reduce obstructive complications and prolong transplant-free survival, via an endoscopic, radiological or surgical approach. UDCA treatment has not been shown to prevent the development of dominant stenoses in uncontrolled trials, although it has not been evaluated as an independent variable⁶⁶.

Sphincterotomy, dilatation and stenting

Endoscopic dilatation of dominant biliary strictures and drainage by sphincterotomy and stenting, may lead to symptomatic, biochemical and radiological improvement in selected cases. The sphincter of Oddi may itself become sclerosed, contributing to biliary obstruction. Sphincterotomy alone has been shown to improve biochemical parameters in small uncontrolled studies; however its predominant role in PSC is to facilitate dilatation, stent placement or stone extraction⁶⁹⁻⁷⁰. Balloon dilatation has been shown to be effective alone in the treatment of dominant strictures⁷¹⁻⁷². Repeated balloon dilatation and stenting has been assessed in retrospective studies of PSC patients taking UDCA, suggesting a trend towards a benefit when comparing jaundice, cholangitis, biochemical cholestasis, transplantation and actuarial survival rates compared with predicted Mayo risk score⁷³⁻⁷⁴. The optimum method and frequency of dilatation remains to be defined.

Retrospective studies evaluating short-term and long-term stenting for dominant strictures have demonstrated improvements in symptoms, cholestasis and rates of

cholangitis⁷⁵⁻⁷⁶. Prospective uncontrolled trials have suggested transplant-free survival advantage of combined UDCA and endoscopic balloon dilatation and/or biliary stent placement, although the relative contribution of each is difficult to ascertain⁶⁶. Long term outcome has yet to be evaluated in randomised controlled trials. Complications from endoscopic therapy have been reported in 7 to 20% of PSC patients^{73,77}. Studies comparing the role of balloon dilatation with stenting have demonstrated similar efficacy but lower complications rates with balloon dilatation alone, especially cholangitis (18% vs. 50%, respectively)⁷¹. Stenting is therefore usually reserved for strictures that are refractory to dilatation.

The percutaneous approach is reserved for those patients with proximal dominant strictures and complex biliary anatomy, often after repeated and/or failed attempts at endoscopic intervention. There are no randomised studies comparing percutaneous transhepatic cholangiography (PTC) with ERCP in stricture management in modern day practice. It is generally accepted, however, that the percutaneous approach is associated with higher morbidity⁷⁸⁻⁷⁹.

Biliary surgery for strictures

Surgery is considered in selected patients without cirrhosis, who have marked cholestasis or recurrent cholangitis due to focal extra-hepatic or hilar strictures, which are not amenable to endoscopic or percutaneous dilatation⁸⁰. In those requiring liver transplant, prior biliary surgery may lead to a longer operation time, greater intra-operative blood loss and high incidence of biliary complications post transplantation, when compared to those with no history of biliary surgery⁸¹⁻⁸³. In those with cirrhosis,

biliary surgery should be avoided as it is associated with high morbidity and mortality.

Resection of the extra-hepatic biliary stricture and Roux Y hepaticojejunostomy, with or without operative stent insertion, may be considered for selected non-cirrhotic PSC patients⁸⁴. It is associated with a readmission-free rate from cholangitis of 57%, 83% and 60% at 3, 5 and 10 years, respectively⁸⁵. However, there is a risk of post-operative infection and scarring in the porta hepatis, which may complicate future transplantation⁸⁶. Biliary bypass by cholangio-enterostomy is infrequently the operation of choice, as most dominant strictures are hilar and intra-hepatic duct involvement limits the access and quality of ducts for bypass⁸⁷. There is no conclusive evidence that surgical intervention alters the natural history or progression of liver disease in patients with PSC.

Bacterial cholangitis

Cholangitis can occur in PSC patients with dominant or tight biliary strictures, co-existing bile duct stones, and in those undergoing endoscopic or percutaneous interventions or surgical exploration. It may be the first presentation of PSC in 6.1% of patients⁸⁸. Recurrent and severe cholangitis may have a role in disease progression. Short courses of antibiotics are often insufficient to eradicate bacteria in the context of an obstructed system; therapeutic drainage in addition is considered more effective⁸⁹. The presence of bacteria in the bile was not associated with reduced survival in one prospective non-randomised study, if stenoses were opened endoscopically and infection was adequately treated with antibiotics⁶⁷. Patients with recurrent bacterial cholangitis may have small benefits from prophylactic long term antibiotics, which

may be rotated to reduce bacterial resistance. Routine bile collection for microbiological analysis during cholangiography may help to define sensitivity of bacteria and guide antibiotic management⁹⁰. In PSC patients with refractory severe bacterial cholangitis, but otherwise preserved liver function, transplantation may be indicated⁹¹.

Malignancy

PSC is associated with an increased risk of hepatobiliary malignancy, particularly CCA. In a large Sweedish cohort of 604 PSC patients, 44% of deaths were due to malignancy; 13.3% due to hepatobiliary carcinoma⁹². Guidelines for screening and surveillance of malignancy in PSC are poorly defined and depend on the individual tumour.

Cholangiocarcinoma

This may present as an intra-hepatic focal carcinoma or more commonly as a ductal infiltrating desmoplastic lesion. CCA has a cumulative lifetime incidence of 10-30% in patients with PSC⁹³. It is found synchronously in 20-30% and within one year of diagnosis in 50%, the yearly developmental rate being 0.5 to 1.5% thereafter^{92,94-96}. There is no clear association between the duration of PSC and the development of CCA; however the presence of cirrhosis may be associated with an increased risk⁹⁷⁻⁹⁸. Deterioration in performance status, biochemical parameters or evidence of a dominant stricture on cholangiogram raises suspicion of CCA, although these may also be manifestations of progressive liver disease. Anatomic location of CCA influences the ease of diagnosis; hilar tumours causing earlier biliary obstruction than small or peripheral intrahepatic lesions⁹⁹. Differentiating benign and malignant

1
2
3 strictures is challenging, currently based on a combination of imaging modalities such
4
5 as MR imaging and multi-slice spiral computer tomography (CT), in addition to
6
7 endoscopic evaluation with brush cytology and/or biopsies of stenotic lesions prior to
8
9 any intervention¹⁰⁰⁻¹⁰¹. The specificity of positive brush cytology is close to 100% but
10
11 sensitivity is low in most centres (17 to 73%); a negative sample not excluding
12
13 malignancy¹⁰²⁻¹⁰³. Digital image analysis and fluorescence in situ hybridisation may
14
15 increase the diagnostic yield of cytology further¹⁰⁴⁻¹⁰⁵. Regular brushing of dominant
16
17 strictures with cytological analysis to detect early neoplastic transformation is adopted
18
19 by some centres.
20
21
22
23
24
25
26

27 There is no reliable screening test for CCA in asymptomatic patients with PSC. In
28
29 those who are symptomatic, serum Ca19-9 levels of >130 U/mL have been reported
30
31 to have a sensitivity of 79% and a specificity of 98% for presence of CCA, although
32
33 this often identifies advanced unresectable CCA which limits its use¹⁰⁶. Some
34
35 clinicians screen asymptomatic patients with annual serum Ca19-9 levels and cross-
36
37 sectional imaging of the hepatobiliary system, although this requires validation^{100,107}.
38
39 In a study of 230 PSC patients, ultrasound, CT and MRI yielded a positive predictive
40
41 value of 48%, 38% and 40%, respectively in identification of CCA¹⁰⁰. Endoscopic
42
43 ultrasound with fine needle aspiration of hilar structures and lymph nodes may aid in
44
45 diagnosis and staging¹⁰⁸⁻¹⁰⁹. The role of FDG-PET is controversial, as inflammation
46
47 can yield false positives in patients with PSC.
48
49
50
51
52
53
54

55 The overall prognosis of patients with PSC complicated by CCA is poor, median
56
57 survival of 5 to 11 months¹¹⁰. Curative extensive surgical resection of early CCA
58
59 gives 3-year survival rates of 20 to 40%, but local recurrence is common due to micro
60

metastases in lymph nodes or surgical margins¹¹¹. Early studies of liver transplant for PSC and CCA did not show a survival benefit; small or incidental CCA found at liver transplant had a 5-year survival of 35%¹¹². Recently, single centre experience in a highly select group of patients with CCA given neo-adjuvant chemoradiation in combination with liver transplant has shown impressive results, with 5-year survival rates of 76 to 82%, similar to that of other indications for transplant¹¹³. This will require validation in other centres¹¹⁴⁻¹¹⁵. The use of brachytherapy and continuous 5-fluoracil infusion before liver transplant in Nebraska resulted in 45% long-term cancer-free survival after follow up of 7.5 years¹¹⁶. External beam radiation therapy is a palliative option in patients with CCA, although it has not been evaluated in the context of PSC¹¹⁷.

Gallbladder polyps and carcinoma

Gallbladder abnormalities have been described in 41% of PSC patients in one large retrospective series¹¹⁸. Gallbladder dysplasia, adenoma and carcinoma have all been described in PSC patients, with a cumulative lifetime incidence of 2%⁹². Gallbladder mass lesions in PSC frequently (>50%) represent adenocarcinomas, independent of their size¹¹⁹⁻¹²⁰. A recent study reported a statistically significant association between hilar and/or intra-hepatic biliary neoplasia and gallbladder neoplasia, suggesting a ‘field defect’ in the biliary tree in PSC¹²¹. Given the high risk of malignancy of gallbladder polyps in PSC, cholecystectomy is advocated for gallbladder lesions of any size in both European and American practice guidelines^{64,122-123}. Annual ultrasound surveillance of the gallbladder has been recommended to detect early abnormalities¹²³.

Pancreatic carcinoma

The risk of pancreatic carcinoma in patients with PSC has been described in a Swedish cohort as 14-fold increased, when compared to a matched-control population⁹². This risk is lower in comparison to other hepatobiliary malignancy in PSC. There is currently no recommended screening for pancreatic disease.

Hepatocellular carcinoma

Cirrhotic patients with PSC are at risk of developing hepatocellular carcinoma (HCC). The cumulative lifetime incidence of HCC in PSC patients is 2%¹²⁴. Screening for HCC in cirrhotic patients, by 6 monthly abdominal imaging and/or alpha-feta protein levels, should follow guidelines as for other cirrhotic chronic liver diseases¹²⁵.

EXTRAHEPATIC COMPLICATIONS

Extra-hepatic complications of PSC include symptomatic pruritis and fatigue, malabsorption and fat-soluble vitamin deficiency, and the development of metabolic bone disease. The management of these complications has been described in detail in the recent European guidelines and is summarised in Table 5¹²³.

INFLAMMATORY BOWEL DISEASE

IBD in patients with PSC

PSC is strongly associated with IBD, with a reported prevalence in Northern Europe and Northern America of 60–80%¹⁴¹⁻¹⁴². IBD often precedes the development of PSC, although it may be diagnosed at any time during its course, even de novo after liver transplantation¹⁴³⁻¹⁴⁴. Ulcerative colitis (UC) accounts for the majority (80%) of cases, while 10% have Crohn's disease (CD) and 10% have indeterminate colitis¹⁴⁵.

1
2
3 Compared to UC patients withoutPSC, the colitis in PSC is more often a
4
5 pancolitis(87% vs. 54%), with backwash ileitis (51% vs. 7%),and rectal sparing (52%
6
7 vs. 6%) and follows a quiescent or prolonged subclinical course¹⁴⁵⁻¹⁴⁷. Patients
8
9 withPSC and CD characteristically havecolonic involvement, although this too is
10
11 extensive¹⁴⁵.
12
13

14
15 Given the strong association with IBD, colonoscopy with biopsies is recommended as
16
17 part of the routine work-up in a patient diagnosed with PSC, even if the patient has no
18
19 symptoms of inflammatory bowel disease.
20
21

22
23
24 PSC patients who have an ileal pouch anal anastomosis(IPAA) after colectomy for
25
26 UC have an increased risk of pouchitiscompared to those with UC alone, which
27
28 should be considered when planning colectomy for aggressive disease¹⁴⁸. Patients
29
30 with an ileostomy after proctocolectomy can develop peristomal varicies, which can
31
32 bleed recurrently and be difficult to manage¹⁴⁹. Local treatments with injection of
33
34 sclerosants, venous ligation and surgical revision are usually unsuccessful, and
35
36 portosystemic shunting or liver transplantation may be necessary to control this
37
38 complication.
39
40
41
42

43
44
45
46 **PSC in patients with IBD**
47

48
49 PSC is diagnosed in between 2.4 to 7.5% of patients with UC,and 3.4% with
50
51 CD^{143,150}. It can be detected at any time during its course, and may present several
52
53 years after proctocolectomy.The prevalence of PSC is higher in those with substantial
54
55 (5.5%) than distal colitis (0.5%)¹⁵¹. Patients with advanced PSC and IBD are more
56
57 likely to be male, asymptomatic on presentation, and have both intra and extrahepatic
58
59
60

bile duct strictures (82% versus 46%) compared to those with PSC alone¹⁵³. There is no routine screening of IBD patients for the presence of PSC.

Colorectal dysplasia and carcinoma

Patients with PSC and UC are at a greater risk of developing colonic dysplasia and carcinoma than those with UC alone; a meta-analysis of 11 studies concluded the risk was increased by approximately fourfold (OR 4.26; 95% CI 2.80 to 6.48)¹⁵³. The absolute cumulative risk seems to increase with disease duration; CRC risk of 9%, 31%, 50% respectively, after 10, 20, 25 years in patients with PSC and UC, compared to 2%, 5% and 10% in those with UC alone¹⁵⁴. The reason for this is unclear, although it is speculated that secondary bile acids play a role in the carcinogenesis of the colorectal mucosa in PSC¹⁵⁵. This is supported by the observation that right-sided cancers are more common in patients with UC and PSC (76%), compared to UC alone¹⁵⁶⁻¹⁵⁷. Patients with PSC and UC continue to have a high risk of CRC after transplantation, with a four-fold increased risk compared to pre-transplantation estimates in one study, perhaps as a result of immunosuppressive medications or the duration of colitis¹⁵⁸.

Diagnosis of IBD has implications for follow-up and dysplasia/cancer surveillance. PSC patients with ulcerative or Crohn's colitis should be enrolled in a surveillance program with annual colonoscopy with biopsies from the time of diagnosis of PSC¹⁵⁹⁻¹⁶¹. This should be continued after liver transplantation in those with an intact colon given the increased CRC risk¹⁶². There is no role for prophylactic colectomy or increased intervals of surveillance in the transplantation setting¹⁵⁸. There is currently no surveillance recommended for PSC patients with pouches.

CIRRHOTIC COMPLICATIONS

PSC may follow a progressive course resulting in portal hypertension and liver failure. A median duration of 12 to 18 years from PSC diagnosis to the development of end-stage liver disease has been observed. Management of cirrhosis and its complications are the same as in other causes of chronic liver disease and has been discussed in detail in the recent European guidelines¹²³.

LIVER TRANSPLANT

Liver transplantation is the treatment of choice in PSC patients with advanced end-stage liver disease, and should be considered when the predicted life expectancy within one year is 85 to 90%. Evaluation of patients with PSC for transplantation is inherently difficult due the unpredictability in disease course and the risk of biliary tract malignancy¹⁶³. Prognostic models may help with timing decisions. The Model for End-Stage Liver Disease (MELD) score has become the primary tool to predict prognosis in and is an aetiology independent method to allocate organs in the United States¹⁶⁴⁻¹⁶⁵. Modified versions, including the United Kingdom End stage Liver Disease (UKELD) score, has been validated to allocate prioritisation for liver transplantation in the UK¹⁶⁶. Indications are outlined in Table 6.

One year and 5 year survival rates for PSC have been reported to be as high as 97% and 88%, respectively, from deceased donor allografts, comparing favourably to transplantation for other indications¹⁶⁷⁻¹⁶⁹. PSC can recur with a rate of 20 to 25% after 5 to 10 years of allograft transplantation, and at a higher rate after living donor transplant, if the graft is obtained from a biologically related donor¹⁷⁰⁻¹⁷². The

diagnosis of recurrence can be challenging, and is based upon consistent findings at liver biopsy and cholangiography, in the absence of other conditions that cause non-anastomotic stricturing¹⁷³. The natural history of recurrent disease is variable; about one third with recurrence developing progressive disease over a 10-year follow up period leading to re-transplantation or death¹⁷⁴. Re-transplantation rates seem higher for patients with PSC compared to other diseases¹⁷⁵. Management after liver transplantation in patients with PSC is similar to other indications, except an increased risk of hepatic osteodystrophy and the role of IBD with increased risk of CRC requiring yearly colonoscopic surveillance.

CONCLUSION

PSC remains a challenging disease to manage. It is important firstly to differentiate PSC from variant forms, each requiring individualised management and follow-up.

Despite considerable advancements, there is still no effective medical therapy that alters the natural history of disease. UDCA in high doses has recently yielded disappointing results, however there is a need to re-evaluate low to moderate doses and to assess new therapies such as the novel bile acid 24-norursodeoxycholic acid to prevent disease progression and provide chemoprotection against biliary and colonic malignancy. Multi-centre randomised controlled trials are essential to evaluate survival, recruiting large number of patients for a long duration of time. Pilot studies are also important in carefully selected patients, given the relative rarity of disease, using more robust markers of efficacy such as serum markers of fibrosis and MRCP.

Dominant strictures are optimally managed with endoscopic dilatation and stenting to relieve biliary obstruction and its complications, after careful exclusion of a malignant

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

stricture. Cholangiocarcinoma remains the most unpredictable and feared complication of PSC, with no reliable screening test yet available, although the outcome in highly selected groups undergoing chemoradiation and liver transplant is promising. Transplantation remains the only option for patients with advanced disease; timing remains problematic due to disease variation and recurrent disease. Further work to understand the pathogenesis of disease, using genome studies, may provide further targets for drug therapy and identify factors that lead to malignant transformation, with the aim of halting its development.

For Peer Review

Declaration of Interests

There are no competing interests.

Financial Support

There was no financial support.

References

1. [Chapman R&Cullen S. Etiopathogenesis of primary sclerosing cholangitis. World J Gastroenterol. 2008 Jun 7;14\(21\):3350-9.](#)
2. [Karlsen TH, Franke A, Melum E, et al. Genome-wide association analysis in primary sclerosing cholangitis. Gastroenterology. 2010 Mar;138\(3\):1102-11.](#)
3. Broome U, Olsson R, Loof L, et al. Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis. Gut. 1996;38:610–15.
4. Abdalian R, Heathcote EJ. Sclerosing cholangitis: a focus on secondary causes. Hepatology 2006;44:1063–1074.
5. Boberg KM, Fausa O, Haaland T, et al. Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis. Hepatology 1996;23:1369–1376.
6. Chapman RW, Cottone M, Selby WS, et al. Serum autoantibodies, ulcerative colitis and primary sclerosing cholangitis. Gut 1986;27:86-91.
7. Mulder AHL, Horst G, Haagsma EB, et al. Prevalence and characterization of neutrophil cytoplasmic antibodies in autoimmune liver diseases. Hepatology 1993;17:411-417.

8. Vitellas KM, El-Dieb A, Vaswani KK, et al. MR cholangiopancreatography in patients with primary sclerosing cholangitis: interobserver variability and comparison with endoscopic retrograde cholangiopancreatography. *AJR Am J Roentgenol* 2002;179:399-407.
9. Dave M, Elmunzer BJ, Dwamena BA, et al. Primary Sclerosing Cholangitis: Meta-Analysis of Diagnostic Performance of MR Cholangiopancreatography [Radiology](#). 2010 Aug; 256(2): 387-96.
10. Harrison RF, Hubscher SG. The spectrum of bile duct lesions in end-stage primary sclerosing cholangitis. [Histopathology](#). 1991 Oct;19(4):321-7
11. Burak KW, Angulo P, Lindor KD. Is there a role for liver biopsy in primary sclerosing cholangitis? *Am J Gastroenterol* 2003;98:1155-1158.
12. Bjornsson E, Olsson R, Bergquist A, et al. The natural history of small-duct primary sclerosing cholangitis. *Gastroenterology* 2008;134:975-980.
13. Broome U, Glaumann H, Lindstrom E, et al. Natural history and outcome in Swedish patients with small duct primary sclerosing cholangitis (PSC). *J Hepatol* 2002;36:586–589.
14. Angulo P, Maor-Kendler Y, Lindor K, et al. Small-duct primary sclerosing cholangitis: A long term follow-up study. *Hepatology* 2002; 35: 1494-500.
15. Bjornsson E, Bomberg KM, Cullen S, et al. Patients with small duct primary sclerosing cholangitis have a favourable long term prognosis. *Gut* 2002; 51: 731-5.
16. Gotthardt D, Runz H, Keitel V, et al. A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults. *Hepatology* 2008;48:1157–1166.

17. [Charatcharoenwitthaya, P, Angulo, P, Enders, FB, Lindor, KD. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis. Hepatology 2008;47:133.](#)
18. Gregorio GV, Portmann B, Karani J, et al. Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16-year prospective study. Hepatology 2001;33:544–553.
19. Al-Chalabi T, Portmann BC, Bernal W, et al. Autoimmune hepatitis overlap syndromes: an evaluation of treatment response, long-term outcome and survival. Aliment Pharmacol Ther 2008;28:209–220.
20. van Buuren HR, van Hoogstraten HJE, Terkivatan T, et al. High prevalence of autoimmune hepatitis among patients with primary sclerosing cholangitis. J Hepatol 2000;33:543–548.
21. Kaya M, Angulo P, Lindor KD. Overlap of autoimmune hepatitis and primary sclerosing cholangitis: an evaluation of a modified scoring system. J Hepatol 2000;33:537–542.
22. Floreani A, Rizzotto ER, Ferrara F, et al. Clinical course and outcome of autoimmune hepatitis/primary sclerosing cholangitis overlap syndrome. Am J Gastroenterol 2005;100:1516–1522.
23. Lewin M, Vilgrain V, Ozeme V, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: A prospective magnetic resonance imaging and histological study. Hepatology 2009;50:528-537.
24. Abdalian R, Dhar P, Jhaveri, et al. Prevalence of sclerosing cholangitis in adults with autoimmune hepatitis: Evaluating the role of routine magnetic resonance imaging. Hepatology 2008;47:949-957.

- 1
2
3 25. Abdo AA, Bain VG, Kichian K, et al. Evolution of autoimmune hepatitis to
4 primary sclerosing cholangitis: a sequential syndrome. *Hepatology*
5
6 2002;36:1393–1399.
7
8
9
10 26. Boberg KM, Egeland T, Schrumpf E. Long-term effect of
11 corticosteroid treatment in primary sclerosing cholangitis patients. *Scand J*
12
13 *Gastroenterol* 2003;38:991-995.
14
15
16
17 27. Bjornsson E, Chari ST, Smyrk TC, et al. Immunoglobulin G4
18 associated cholangitis: description of an emerging clinical entity based on
19 review of the literature. *Hepatology* 2007;45:1547-1554.
20
21
22
23
24 28. Ghazale A, Chari ST, Zhang L et al, Immunoglobulin-4 associated cholangitis:
25 clinical profile and response to therapy. *Gastroenterology*, 2008;134:706-15.
26
27
28
29 29. Dastis SN, Latinne D, Sempoux C, et al. Ulcerative colitis associated with
30 IgG4 cholangitis: similar features in two HLA identical siblings. *J Hepatol*.
31 2009 Sep;51(3):601-5.
32
33
34
35 30. [Narula N](#), [Vasudev M](#), [Marshall JK](#). IgG(4)-Related Sclerosing Disease: A
36 Novel Mimic of Inflammatory Bowel Disease. [Dig Dis Sci](#). 2010;55(11):3047-
37 3051.
38
39
40
41
42
43 31. Mendes FD, Jorgensen R, Keach J, et al. Elevated serum IgG4 concentration
44 in patients with primary sclerosing cholangitis. *Am J Gastroenterol*
45 2006;101:2070-2075.
46
47
48
49
50 32. Zhang L, Lewis JT, Abraham SC, et al. IgG4+ plasma cell infiltrates in liver
51 explants with primary sclerosing cholangitis. [Am J Surg Pathol](#). 2010
52 Jan;34(1):88-94
53
54
55
56
57
58
59
60

- 1
2
3 33. Oh HC, Kim MH, Lee KT, et al. Clinical clues to suspicion of IgG4-
4 associated sclerosing cholangitis disguised as primary sclerosing cholangitis or
5
6 hilar cholangiocarcinoma. *J Gastroenterol Hepatol*. 2010 Dec;25(12):1831-7
7
8
9
10 34. Chung H, Watanabe T, Kudo M, et al. Identification and characterization of
11
12 IgG4-associated autoimmune hepatitis *Liver Intern* 2010;30(10)222-231.
13
14
15 35. Topazian M, Witzig TE, Smyrk TC, et al. Rituximab therapy for refractory
16
17 biliary strictures in immunoglobulin G4 associated cholangitis. *Clin*
18
19 *Gastroenterol Hepatol* 2008;6:364-6.
20
21
22 36. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model
23
24 for primary sclerosing cholangitis. *Mayo Clin Proc* 2000;75:688-94.
25
26
27 37. Kim WR, Poterucha JJ, Wiesner RH, et al. The relative role of the Child-Pugh
28
29 classification and the Mayo natural history model in the assessment of survival
30
31 in patients with primary sclerosing cholangitis. *Hepatology* 1999;29:1643-
32
33 1648.
34
35
36 38. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and
37
38 outcomes of primary sclerosing cholangitis in a United States community.
39
40 *Gastroenterology* 2003;125:1364-1369
41
42
43 39. Ponsioen CY, Vrouenraets SM, Prawirodirdjo W, et al. Natural history of
44
45 primary sclerosing cholangitis and prognostic value of cholangiography in a
46
47 Dutch population. *Gut* 2002;51:562-6.
48
49
50 40. Mendes FD, Kim WR, Pedersen R, et al. Mortality attributable to cholestatic
51
52 liver disease in the United States. *Hepatology* 2008;47:1241-7.
53
54
55 41. Paumgartner G, Beuers U. Ursodeoxycholic acid in cholestatic liver diseases
56
57 *Hepatology* 2002;36:525-531.
58
59
60

- 1
2
3 42. Martinez JD, Stratagoules ED, La Rue JM, et al. Different bile acids exhibit
4
5 distinct biological effects: the tumour promoter deoxycholic acid induces
6
7 apoptosis and the chemopreventive agent ursodeoxycholic acid inhibits cell
8
9 proliferation. *Nutr Cancer* 1998;31:111-118.
10
11
12 43. Beuers U, Spengler U, Kruis W, et al. Ursodeoxycholic acid for treatment of
13
14 primary sclerosing cholangitis: a placebo-controlled trial. *Hepatology*
15
16 1992;16:707-714.
17
18
19 44. Chazouilleres O, Poupon R, Capron JP, et al. Ursodeoxycholic acid for
20
21 primary sclerosing cholangitis. *J Hepatol* 1990;11:120-123
22
23
24 45. O'Brien CB, Senior JR, Arora-Mirchandani R, et al. Ursodeoxycholic acid for
25
26 the treatment of primary sclerosing cholangitis: a 30-month pilot study.
27
28 *Hepatology* 1991;14:838-847
29
30
31 46. Stiehl A. Ursodeoxycholic acid therapy in treatment of primary sclerosing
32
33 cholangitis. *Scand J Gastroenterol Suppl* 1994;204:59-61.
34
35
36 47. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo primary
37
38 Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. *N Engl J Med*
39
40 1997;336:691-695
41
42
43 48. Lindor KD, Kowdley KV, Luketic VAC, et al. High dose ursodeoxycholic
44
45 acid for the treatment of primary sclerosing cholangitis. *Hepatology*
46
47 2009;50(3):808-14.
48
49
50 49. Mitchell SA, Bansi DS, Hunt N, et al. A preliminary trial of high-dose
51
52 ursodeoxycholic acid in primary sclerosing cholangitis.
53
54 *Gastroenterology* 2001;121:900-907
55
56
57
58
59
60

- 1
2
3 50. Olsson R, Boberg KM, de Muckadell OS, et al. High-dose ursodeoxycholic
4 acid in primary sclerosing cholangitis: a 5-year multicentre, randomized,
5 controlled study. *Gastroenterology* 2005;129:1464-1472
6
7
8
9
10 51. Cullen SN, Rust C, Fleming K, et al. High dose ursodeoxycholic acid for the
11 treatment of primary sclerosing cholangitis is safe and effective. *J Hepatol*
12 2008;48:792–800.
13
14
15
16
17 52. Lindor KD, Enders FB, Schmoll JA, et al. Randomized, double-blind
18 controlled trial of high-dose ursodeoxycholic acid for primary sclerosing
19 cholangitis. *Hepatology* 2008;47:133-142.
20
21
22
23
24 53. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates
25 bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of
26 cholangioles. *Gastroenterology* 2002;123:1238-1251.
27
28
29
30
31 54. Beneditti A, Alvaro D, Bassotti C, et al. Cytotoxicity of bile salts against
32 biliary epithelium: a study in isolated bile ductile fragments and isolated
33 perfused rat liver. *Hepatology* 1997;26:9-21.
34
35
36
37
38 55. [Sinakos E](#), [Marschall HU](#), [Kowdley KV](#), et al. Bile acid changes after high-
39 dose ursodeoxycholic acid treatment in primary sclerosing cholangitis:
40 Relation to disease progression. *Hepatology*, 2010;52(1):197-203.
41
42
43
44
45 56. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower
46 prevalence of colonic neoplasia in patients with ulcerative colitis and primary
47 sclerosing cholangitis. *Ann Intern Med* 2001;134: 89-95.
48
49
50
51
52 57. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a
53 chemopreventive agent in patients with ulcerative colitis and primary
54 sclerosing cholangitis. *Gastroenterology* 2003;124:889-893.
55
56
57
58
59
60

- 1
2
3 58. Wolf JM, Rybicki LA, Lashner BA. The impact of ursodeoxycholic acid
4
5 cancer, dysplasia and mortality in ulcerative colitis patients with
6
7 primary sclerosing cholangitis. *Aliment Pharmacol Ther* 2005;22:783-788.
8
9
- 10 59. Rudolph G, Kloeters-Plachky P, Rost D, et al. The incidence of
11
12 cholangiocarcinoma in primary sclerosing cholangitis after long-time treatment
13
14 with ursodeoxycholic acid. *Eur J Gastroenterol Hepatol* 2007;19:487-491.
15
16
- 17 60. Brandsaeter B, Isoniemi H, Broome U, et al. Liver transplantation for primary
18
19 sclerosing cholangitis; predictors and consequences of hepatobiliary
20
21 malignancy. *J Hepatol* 2004;40:815-822.
22
23
- 24 61. Halilbasic E, Fiorotto R, Fickert P, et al. Sidechain structure determines
25
26 unique physiologic and therapeutic properties of norursodeoxycholic acid in
27
28 Mdr^{-/-} mice. *Hepatology* 2009;49:1972-82.
29
30
- 31 62. Glaser SS, Alpini G, Hightower NC. Activation of the cholehepatic shunt as a
32
33 potential therapy for primary sclerosing cholangitis. *Hepatology*
34
35 2009;49:1790-2.
36
37
- 38 63. Cullen SN, Chapman RW. Review article: current management of primary
39
40 sclerosing cholangitis. *Aliment Pharmacol Ther* 2005;21:933-948.
41
42
- 43 64. Chapman R, Fevery J, Kalloo A, et al. AASLD Practice Guidelines: Diagnosis
44
45 and management of primary sclerosing cholangitis. *Hepatology*
46
47 2010;51(2):660-78.
48
49
- 50 65. Bjornsson E, Lindqvist-Ottosson J, Asztely M, et al. Dominant strictures in
51
52 patients with primary sclerosing cholangitis. *Am J Gastroenterol* 2004;99:502-
53
54 508.
55
56
- 57 66. Stiehl A, Rudolph G, Kloeters-Plachky P, et al. Development of dominant bile
58
59 duct stenoses in patients with primary sclerosing cholangitis treated with
60

- ursodeoxycholic acid: outcome after endoscopic treatment. *J Hepatol* 2002;36:151-156.
67. Rudolph G, Gotthardt D, Klöters-Plachky P, et al. Influence of dominant bile duct stenoses and biliary infections on outcome in primary sclerosing cholangitis. *J Hepatol* 2009;51(1):149-55.
68. Lindberg B, Arnelo U, Bergquist A, et al. Diagnosis of biliary strictures in conjunction with endoscopic retrograde cholangiopancreatography, with special reference to patients with primary sclerosing cholangitis. *Endoscopy* 2002;34:909-916.
69. Gaing AA, Geders JM, Cohen SA, et al. Endoscopic management of primary sclerosing cholangitis: review, and report of an open series. *AmJ Gastroenterol* 1993;88:2000-08.
70. Johnson GK, Geenen JE, Venu RP, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. *Gastrointest Endosc* 1991;37:38-43.
71. Kaya M, Petersen BT, Angulo P, et al. Balloon dilation compared to stenting of dominant strictures in primary sclerosing cholangitis. *Am J Gastroenterol* 2001;96:1059-1066.
72. Gaing AA, Geders JM, Cohen SA, et al. Endoscopic therapy for primary sclerosing cholangitis: Report of an ongoing series. *Gastrointest Endosc* 1992;38:261-262.
73. Baluyut AR, Sherman S, Lehman GA, et al. Impact of endoscopic therapy on the survival of patients with primary sclerosing cholangitis. *Gastrointest Endosc* 2001;53:308-312.

74. Stiehl A, Rudolph G, Sauer P, et al. Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis: an 8-year prospective study. *J Hepatol* 1997;26:560–566.
75. Johnson GK, Geenen JE, Venu RP, et al. Endoscopic treatment of biliary tract strictures in sclerosing cholangitis: a larger series and recommendations for treatment. *Gastrointest Endosc* 1991;37:38–43.
76. van Milligen de Wit AW, van Bracht J, Rauws EA, et al. Endoscopic stent therapy for dominant extrahepatic bile duct strictures in primary sclerosing cholangitis. *Gastrointest Endosc* 1996;44:293–299.
77. [Bangarulingam SY](#), [Gossard AA](#), [Petersen BT](#), et al. Complications of endoscopic retrograde cholangiopancreatography in primary sclerosing cholangitis. [Am J Gastroenterol](#). 2009 Apr;104(4):855–60.
78. [Eickhoff A](#) et al, Long-term outcome of percutaneous transhepatic drainage for benign bile duct stenoses. [Rocz Akad Med Bialymst](#). 2005;50:155–60.
79. Ahrendt SA, Pitt HA, Kalloo AN, et al. Primary sclerosing cholangitis: resect, dilate, or transplant? *Ann Surg* 1998;227:412–423.
80. Angulo P, Lindor KD. Primary sclerosing cholangitis. *Hepatology* 1999;30:325–32.
81. Farges O, Malassagne B, Sebag M, et al. Primary sclerosing cholangitis: liver transplantation or biliary surgery. *Surgery*, 1995;117:146–55.
82. Muiesan P, Shanmugam RP, Delvin J, et al. Orthotopic liver transplantation for primary sclerosing cholangitis. *Transplant Proc*, 1994;26:3574–76.
83. Narumi S, Roberts JP, Emond JC, et al. Liver transplant for sclerosing cholangitis. *Hepatology* 1995;22:451–57.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
84. [Tsai S](#), [Pawlik TM](#). Primary sclerosing cholangitis: the role of extrahepatic biliary resection. [Adv Surg](#). 2009;43:175-88.
85. Pawlick TM, Olbrecht VA, Pitt HA, et al. Primary sclerosing cholangitis: role of extrahepatic biliary resection. *J Am Coll Surg* 2008;206:822-830.
86. Cameron JL, Pitt HA, Zinner MJ, et al. Resection of hepatic duct bifurcation and transhepatic stenting for sclerosing cholangitis. *Ann Surg* 1988;207:614-622.
87. Myburgh JA. Surgical biliary drainage in primary sclerosing cholangitis. The role of the Hepp-Couinaud approach. *Arch Surg* 1994;129:1057-1062.
88. Kaplan GG, Laupland KB, Butzner D, et al. The burden of large and small duct primary sclerosing cholangitis in adults and children: a population-based analysis. *Am J Gastroenterol* 2007;102:1042-1049.
89. Pohl J, Ring A, Stremmel W, Stiehl A. The role of dominant stenoses in bacterial infections of bile ducts in primary sclerosing cholangitis. *Eur J Gastroenterol Hepatol* 2006;18:69-74.
90. [Negm AA](#), [Schott A](#), [Vonberg RP](#), et al. Routine bile collection for microbiological analysis during cholangiography and its impact on the management of cholangitis. [Gastrointest Endosc](#). 2010;72(2):284-291.
91. Abraham SC, Kamath PS, Egtesad B, et al. Liver transplantation in precirrhotic biliary tract disease: Portal hypertension is frequently associated with nodular regenerative hyperplasia and obliterative portal venopathy. *Am J Surg Pathol* 2006;30:1454-1461.
92. [Bergquist A](#), [Ekblom A](#), [Olsson R](#), Hepatic and extrahepatic malignancies in primary sclerosing cholangitis. [J Hepatol](#). 2002 Mar;36(3):321-7.

93. Maggs JR, Chapman RW. An update on primary sclerosing cholangitis. *Curr Opin Gastroenterol* 2008;24:377-383.
94. Burak K, Angulo P, Pasha TM, et al. Incidence and risk factors for cholangiocarcinoma in primary sclerosing cholangitis. *Am J Gastroenterol*, 2004;99:523-26.
95. Boberg KM, Bergquist A, Mitchell S, et al. Cholangiocarcinoma in primary sclerosing cholangitis: risk factors and clinical presentation. *Scand J Gastroenterol*, 2002;37:1205-11.
96. Kornfeld D, Ekbom A, Ihre T. Survival and risk of cholangiocarcinoma in patients with primary sclerosing cholangitis. A population based study. *Scand J Gastroenterol* 1997;32:1042-5.
97. Helzberg JH, Petersen JM, Boyer JL. Improved survival with primary sclerosing cholangitis. A review of clinicopathologic features and comparison of symptomatic and asymptomatic patients. *Gastroenterol* 1987;92:1869-75.
98. Lazaridis KN, Gores GJ. Primary sclerosing cholangitis and cholangiocarcinoma. *Semin Liver Dis* 2006;26:42-51.
99. Yachimski P, Pratt DS. Cholangiocarcinoma: Natural history, treatment and strategies for surveillance in high risk patients. *J Clin Gastroenterol* 2008;42:178-90.
100. Charatchoenwittaya P, Enders FB, Halling KC, et al. Utility of serum tumor markers, imaging, and biliary cytology for detecting cholangiocarcinoma in primary sclerosing cholangitis. *Hepatology* 2008;48:1106-1117.

- 1
2
3 101. Angulo P, Pearce DH, Johnson CD, et al. Magnetic resonance
4
5
6 cholangiography in patients with biliary disease: its role in primary sclerosing
7
8
9 cholangitis. *J Hepatol* 2000;33:520-7.
- 10
11 102. Rabinovitz M, Zajko AM, Hassanein T et al. Diagnostic value of brush
12
13
14 cytology in the diagnosis of bile duct carcinoma: A study of 65 patients with
15
16
17 bile duct strictures. *Hepatology* 1990;12:747-52.
- 18
19 103. Boberg KM, Jebsen P, Clausen OP, et al. Diagnostic benefit of biliary
20
21
22 brush cytology in cholangiocarcinoma in primary sclerosing cholangitis. *J*
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
Hepatol. 2006;45:568-74.
104. Moreno Luna LE, Kipp B, Halling KC, et al. Advanced cytological
techniques for the detection of malignant pancreatobiliary strictures.
Gastroenterology 2006;131:1064-72.
105. Kipp BR, Stadheim LM, Halling SA, et al. A comparison of routine
cytology and fluorescence in situ hybridisation for the detection of malignant
bile duct strictures. *Am J Gastroenterol*, 2004;99:1675-81.
106. Levy C, Lymp J, Angulo P, et al. The value of serum CA 19-9 in
predicting cholangiocarcinomas in patients with primary sclerosing
cholangitis. *Dig Dis Sci* 2005;50:1734-40.
107. Steinberg W. The clinical utility of the CA 19-9 tumor-associated
antigen. *Am J Gastroenterol* 1990;85:350-355.
108. Fritscher-Ravens A, Broering DC, Knoefel WT, et al. EUS-guided
fine-needle aspiration of suspected hilar cholangiocarcinoma in potentially
operable patients with negative brush cytology. *Am J Gastroenterol*
2004;99:45-51.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
109. Gleeson FC, Rajan E, Levy MJ, et al. EUS-guided FNA of regional lymph nodes in patients with unresectable hilar cholangiocarcinoma. *Gastrointest Endosc* 2008;67:438-443.
110. Fevery J, Verslype C, Lai G, et al. Incidence, diagnosis and therapy of cholangiocarcinoma in patients with primary sclerosing cholangitis. *Dig Dis Sci*, 2007;52:3123-35.
111. Meza-Junco J, Montano-Loza AJ, Ma M, et al. Cholangiocarcinoma: has there been any progress. *Can J Gastroenterol*. 2010 Jan;24(1):52-7.
112. Iiwatsuki S, Todo S, Marsh JW, et al. Treatment of hilar cholangiocarcinoma (Klatskin tumours) with hepatic resection or transplantation. *J Am Coll Surg* 1998;187:358-64.
113. Rea DJ, Heimbach JK, Rosen CB, et al. Liver transplantation with neoadjuvant chemoradiation is more effective than resection for hilar cholangiocarcinoma. *Ann Surg* 2005;242:451-458; discussion 458-461.
114. Heimbach JK, Gores GJ, Nagorney DM, et al. Liver transplantation for perihilar cholangiocarcinoma after aggressive neoadjuvant therapy: a new paradigm for liver and biliary malignancies? *Surgery* 2006;140:331-4.
115. Gores GJ, Nagorney DM, Rosen CB. Cholangiocarcinoma: is transplantation an option? For whom? *J Hepatol* 2007;47:455-459.
116. Sudan D, DeRoover A, Chinnakotla S, et al. Radiochemotherapy and transplantation allow long-term survival for non-resectable hilar cholangiocarcinoma. *Am J Transplant* 2002;2:774-9.
117. Kahaleh M, Mishra R, Shami VM, et al. Unresectable cholangiocarcinoma: comparison of survival in biliary stenting alone versus

- stenting with photodynamic therapy. Clin Gastroenterol Hepatol 2008;6:290-297.
118. Brandt DJ, MacCarty RL, Charboneau JW, et al. Gallbladder disease in patients with primary sclerosing cholangitis. Am J Roentgenol 1988;150:571-574.
119. Said K, Glaumann H, Bergquist A. Gallbladder disease in patients with primary sclerosing cholangitis. J Hepatol 2008;48:598–605.
120. Buckles DC, Lindor KD, Larusso NF, et al. In primary sclerosing cholangitis, gallbladder polyps are frequently malignant. Am J Gastroenterol 2002;97:1138-1142.
121. Lewis JT, Talwalker JA, Rosen CB, et al. prevalence and risk factors for gallbladder neoplasia in patients with primary sclerosing cholangitis: evidence for metaplasia-dysplasia-carcinoma sequence. Am J Surg Pathol, 2007;31:907-13.
122. Leung UC, Wong PY, Roberts RH, et al. Gallbladder polyps in sclerosing cholangitis: does the 1cm rule apply? ANZ J Surg 2007;77:355-57.
123. Beuers U, Boberg K, Chapman RW, et al. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009;51:237-67.
124. Harnois DM, Gores GJ, Ludwig J, et al. Are patients with cirrhotic stage primary sclerosing cholangitis at risk for the development of hepatocellular cancer? J Hepatol 1997;27:512–516.
125. Bruix J & Sherman M. AASLD Practice Guidelines: Management of Hepatocellular Carcinoma. Hepatology, 2005;42(5):1208-35. Updated Hepatology, 2010;1-35.

- 1
2
3 126. Jones EA, Bergasa NV. The pruritis of cholestasis. *Hepatology*
4
5 1999;29:1003-6
6
7
8 127. Datta DV, Sherlock S. Cholestyramine for long term relief of pruritus
9
10 complicating intrahepatic cholestasis. *Gastroenterology*.1966;50:323–332.
11
12 128. Polter DE, Gruhl V, Eigenbrodt EH, et al. Beneficial effects of
13
14 cholestyramine in sclerosing cholangitis. *Gastroenterology* 1980;79:326-33.
15
16 129. Khurana S, Singh P. Rifampin is safe for the treatment of pruritus due
17
18 to chronic cholestasis: a meta-analysis of prospective randomized-controlled
19
20 trials. *Liver Int* 2006;26:943–948.
21
22 130. Tandon P, Rowe BH, Vandermeer B, et al. The efficacy and safety of
23
24 bile acid binding agents, opioid antagonists or rifampicin in the treatment of
25
26 cholestasis-associated pruritus *Am J Gastroenterol* 2007;102:1528–1536.
27
28 131. Wolfhagen FH, Sternieri E, Hop WC, et al. Oral naltrexone treatment
29
30 for cholestatic pruritus: a double-blind, placebo-controlled study.
31
32 *Gastroenterology* 1997;113:1264-1269.
33
34 132. Bergasa NV, Alling DW, Talbot TL, et al. Effects of naloxone
35
36 infusions in patients with the pruritus of cholestasis. A double-blind,
37
38 randomized, controlled trial. *Ann Intern Med* 1995;123:161-67.
39
40 133. Jones EA, Molenaar HA, Oosting J. Ondansetron and pruritus in
41
42 chronic liver disease: a controlled study. *Hepatogastroenterology*
43
44 2007;54:1196-1199.
45
46 134. Mayo MJ, Handem I, Saldana S, Jacobe H, Getachew Y, Rush AJ.
47
48 Sertraline as a first-line treatment for cholestatic pruritus. *Hepatology*
49
50 2007;45:666-74.
51
52
53
54
55
56
57
58
59
60

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
135. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. *Dig Dis Sci* 2004;49:1-4.
136. Jones DE, Newton JL. An open study of modafinil for the treatment of daytime somnolence and fatigue in primary biliary cirrhosis. *Aliment Pharmacol Ther* 2007;25:471-76.
137. Angulo P, Therneau TM, Jorgensen A, et al. Bone disease in patients with primary sclerosing cholangitis: prevalence, severity and prediction of progression. *J Hepatol* 1998;29:729-735.
138. Porayko MK, Wiesner RH, Hay JE, et al. Bone disease in liver transplant recipients: incidence, timing, and risk factors. *Transplant Proc* 1991;23:1462-1465.
139. Pares A, Guanabens N. Osteoporosis in primary biliary cirrhosis: pathogenesis and treatment. *Clin Liver Dis* 2008;12:407-24.
140. Pereira SP, O'Donohue J, Moniz C, et al. Transdermal hormone replacement therapy improves vertebral bone density in primary biliary cirrhosis: results of a one year controlled trial. *Aliment Pharmacol Therap* 2007;25:471-76.
141. Wiesner RH, Grambsch PM, Dickson ER, et al. Primary sclerosing cholangitis: natural history, prognostic factors and survival analysis. *Hepatology* 1989;10:430-436.
142. Chapman RW, Arborgh BA, Rhodes JM, et al. Primary sclerosing cholangitis: a review of its clinical features, cholangiography, and hepatic histology. *Gut* 1980;21:870-877.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
143. Fausa O, Schrumpf E, Elgjo K. Relationship of inflammatory
boweldisease and primary sclerosing cholangitis. *Semin Liver Dis* 1991;11:31-
39.
144. Verdonk RC, Dijkstra G, Haagsma EB, et al. Inflammatory bowel
disease after liver transplantation: risk factors for recurrence and de novo
disease. *Am J Transplant* 2006;6:1422-1429.
145. Loftus Jr EV, Harewood GC, Loftus CG, et al. PSC-IBD: a unique
formof inflammatory bowel disease associated with primary sclerosing
cholangitis. *Gut* 2005;54:91-96.
146. Broome U, Bergquist A. Primary sclerosing cholangitis, inflammatory
bowel disease, and colon cancer. *Semin Liver Dis* 2006;26:31-41.
147. Lundqvist K, Broome U. Differences in colonic disease activity in
patients with ulcerative colitis with and without primary sclerosing
cholangitis: a case control study. *Dis Colon Rectum* 1997;40:451-456.
148. Penna C, Dozois R, Tremaine W, et al. Pouchitis after ileal pouch-anal
anastomosis for ulcerative colitisoccurs with increased frequency in patients
with associated primary sclerosing cholangitis. *Gut* 1996;38:234-239.
149. Wiesner RH, LaRusso NF, Dozois RR, et al. Peristomal varices after
proctocolectomy in patients with primary sclerosing cholangitis.
Gastroenterology 1986;90:316-322.
150. Schrumpf E, Elgjo K, Fausa O, et al. Sclerosing cholangitis in
ulcerative colitis. *Scand J Gastroenterol* 1980;15:689-697.
151. Olsson R, Danielsson A, Jarnerot G, et al. Prevalence of primsary
sclerosing cholangitis in ulcerative colitis. *Gastroenterology* 1991;100:1319-
23

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
152. Rabinovitz M, Gavalier JS, Schade RR, et al. Does primary sclerosing cholangitis occurring in association with inflammatory bowel disease differ from that occurring in the absence of inflammatory bowel disease? A study of sixty-six subjects. *Hepatology* 1990;11(1):7-11.
153. Soetikno RM, Lin OS, Heidenreich PA, et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. *Gastrointest Endosc* 2002;56:48-54.
154. Broome, U, Lofberg, R, Veress, B, Eriksson, LS. Primary sclerosing cholangitis and ulcerative colitis: Evidence for increased neoplastic potential. *Hepatology* 1995; 22:1404.
155. Naggengast F, Grubben M, van Munster I. Role of bile acids in colorectal carcinogenesis. *Eur J Cancer*. 1995;31:1067–1070.
156. Shetty K, Rybicki L, Brzezinski A, et al. The risk for cancer or dysplasia in ulcerative colitis patients with primary sclerosing cholangitis. *Am J Gastroenterol* 1999;94:1643-1649.
157. Marchesa, P, Lashner, BA, Lavery, IC, et al. The risk of cancer and dysplasia among ulcerative colitis patients with primary sclerosing cholangitis. *Am J Gastroenterol* 1997; 92:1285.
158. Loftus Jr EV, Aguilar HI, Sandborn W, et al. Risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis following orthotopic liver transplantation. *Hepatology* 1998;27(3):685-90.
159. Cairns S, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups. *Gut* 2010;59:666-689.

- 1
2
3 160. Kaplan GG, Heitman SJ, Hilsden RJ, et al. Population-based analysis
4 of practices and costs of surveillance for colonic dysplasia in patients with
5 primary sclerosing cholangitis and colitis. *Inflamm Bowel Dis* 2007;13:1401-
6 1407.
7
8
9
10
11
12 161. Kitiyakara T, Chapman RW. Chemoprevention and screening in
13 primary sclerosing cholangitis. *Postgrad Med J* 2008;84:228-37.
14
15
16
17 162. MacLean AR. Outcome of Patients Undergoing Liver Transplantation
18 for Primary Sclerosing Cholangitis. *Dis Colon Rectum* 2003;46(8):1124-28.
19
20
21
22 163. Bjørø K, Brandsaeter B, Foss A, Schrumpf E. Liver transplantation in
23 primary sclerosing cholangitis. *Semin Liver Dis.* 2006 Feb;26(1):69-79.
24
25
26
27 164. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD:
28 application of survival models to liver allocation. *Liver Transpl* 2001;7:567-
29 580.
30
31
32
33
34 165. Freeman RB, Edwards EB, Harper AM. Waiting list removal rates
35 among patients with chronic and malignant liver diseases. *Am J Transplant*
36 2006;6:1416-1421.
37
38
39
40
41 166. Neuberger J, Gimson A, Davies M, et al. Selection of patients for liver
42 transplantation and allocation of donated livers in the UK. *Gut* 2008;57:252-
43 257.
44
45
46
47
48 167. Brandsaeter B, Friman S, Broome U, et al. Outcome following liver
49 transplantation for primary sclerosing cholangitis in the Nordic countries.
50
51
52
53
54
55 168. Graziadei IW, Wiesner RH, Marotta PJ, et al. Long-term results of
56 patients undergoing liver transplantation for primary sclerosing cholangitis.
57
58
59
60
60 *Hepatology* 1999;30:1121-1127.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
169. Roberts MS, Angus DC, Bryce CL, et al. Survival after liver transplantation in the United states : A disease specific analysis of the UNOS database. *Liver Transpl* 2004;10:886-97.
170. Campsen J, Zimmerman MA, Trotter JF, et al. Clinically recurrent primary sclerosing cholangitis following livertransplantation: a time course. *Liver Transpl* 2008;14:181-185.
171. Graziadei IW, Wiesner RH, Batts KP, et al. Recurrence of primary sclerosing cholangitis following liver transplantation. *Hepatology* 1999;29:1050-6.
172. Tamura S, Sugawara Y, Kaneko J, et al. Recurrence of primary sclerosing cholangitis after living donor transplantation. *Liver Int* 2007;27:86-94.
173. Wojcicki M, Milkiewicz P, Silva M. Biliary tract complications after livertransplantation: a review. *Dig Surg* 2008;25:245-257.
174. Alabraba E, Nightingale P, Gunson B, at el. A re-evaluation of the risk factors for the recurrence of primary sclerosing cholangitis in liver allografts. *Liver Transplant* 2009;15(3):330-40.
175. La Russo NF, Shneider BL, Black D, et al. Primary sclerosing cholangitis: summary of a workshop. *Hepatology* 2006;44:746-64.
176. Lo SK, Hermann R, Chapman RW, et al. Ursodeoxycholic acid in primary sclerosing cholangitis.: a double blind placebo controlled trial. *Hepatology* 1992;16:92A.
177. Stiehl A, Walker S, Stiehl L, Rudolph G, Hofmann WJ, Theilmann L. Effect of ursodeoxycholic acid on liver and bile duct disease in primary

- sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period. *J Hepatol* 1994;20:57-64.
178. De Maria N, Colantoni A, Rosenbloom E, et al. Ursodeoxycholic acid does not improve the clinical course of primary sclerosing cholangitis over a 2 year period. 1996;43:1472-9.
179. Van Hoogstraten HJ, Wolfhagen FH, van de Meeberg PC, et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: results of a 2year randomised controlled trial to evaluate single vs. multiple daily disease. *J Hepatol* 1998;29:417-23.
180. Harnois DM, Angulo P, Jorgensen RA, LaRusso NF, Lindor KD. Highdose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis. *Am J Gastroenterol* 2001;96:1558-1562.
181. Okolicsanyi L, Groppo M, Floreani A, Morselli-Labate AM, Rusticali AG, Battocchia A, et al. Treatment of primary sclerosing cholangitis with lowdose ursodeoxycholic acid: results of a retrospective Italian multicentresurvey. *Dig Liver Dis* 2003;35:325-331.
182. Angulo P, Batts KP, Jorgensen RA, et al. Oral budesonide in the treatment of primary sclerosing cholangitis. *Am J Gastroenterol* 2000;95:2333-7.
183. [Knox, TA, Kaplan, MM. Treatment of primary sclerosing cholangitis with oral methotrexate. *Am J Gastroenterol* 1991;86:546.](#)
184. Knox TA, Kaplan MM. A double-blind controlled trial of oral-pulse methotrexate therapy in the treatment of primary sclerosing cholangitis. *Gastroenterology* 1994;106:494-9.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
185. Sandborn WJ, Wiesner RH, Tremaine WJ, et al. Ulcerative colitis disease activity following treatment of associated primary sclerosing cholangitis with cyclosporin. *Gut* 1993;34:242-6.
186. Van Thiel DH, Carroll P, Abu-Elmagd K, et al. Tacrolimus (FK506), a treatment for primary sclerosing cholangitis: Results of an open-label preliminary trial. *Am J Gastroenterol* 1995;90:455-9.
187. Olsson R, Broome U, Danielsson A, et al. Colchicine treatment of primary sclerosing cholangitis. *Gastroenterology* 1995;108:1199-203.
188. LaRusso NF, Wiesner RH, Ludwig J, et al. Prospective trial of penicillamine in primary sclerosing cholangitis. *Gastroenterology* 1988;95:1036-42.
189. Bharucha AE, Jorgensen R, Lichtman SN, et al. A pilot study of pentoxifylline for the treatment of primary sclerosing cholangitis. *Am J Gastroenterol* 2000;95:2338-42.
190. Duchini A, Younossi ZM, Saven A, et al. An open-label pilot trial of cladibine (2-cholordeoxyadenosine) in patients with primary sclerosing cholangitis. *J Clin Gastroenterol* 2000;31:292-6.
191. Angulo P, MacCarty RL, Sylvestre PB, et al. Pirfenidone in the treatment of primary sclerosing cholangitis. *Dig Dis Sci* 2002;47:157-61.
192. Angulo P, Bharucha AE, Jorgensen RA, et al. Oral nicotine in treatment of primary sclerosing cholangitis: A pilot study. *Dig Dis Sci* 1999;44:602-7.
193. Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, et al. No beneficial effects of transdermal nicotine in patients with primary sclerosing

- cholangitis: Results of a randomized double-blind placebo-controlled cross-over study. *Eur J Gastroenterol Hepatol* 2001;13:171-5.
194. Epstein MP, Kaplan MM. A pilot study of etanercept in the treatment of primary sclerosing cholangitis. *Dig Dis Sci* 2004;49:1-4.
195. Talwalkar JA, Angulo P, Keach JC, et al. Lindor KD. Mycophenolate mofetil for the treatment of primary sclerosing cholangitis. *Am J Gastroenterol* 2005;100:308-12.
196. Talwalkar JA, Gossard AA, Keach JC, et al. Tacrolimus for the treatment of primary sclerosing cholangitis. *Liver Int* 2007;27:451-3.
197. Hommes DW, Erkelens W, Ponsioen C, et al. A double-blind, placebo-controlled, randomized study of infliximab in primary sclerosing cholangitis. *J Clin Gastroenterol* 2008;42:522-6.
198. Angulo P, Jorgensen RA, Kowdley KV, Lindor KD. Silmarin in the treatment of patients with primary sclerosing cholangitis: an open label pilot study. *Dig Dis Sci* 2008 Jun;53(6):1716-20.
199. Mizuno S, Hirano K, Tada M, et al. Bezafibrate for the treatment of primary sclerosing cholangitis. *J Gastroenterol* 2010 Feb (online).
200. [Lindor, KD, Wiesner, RH, Colwell, L, et al. The combination of prednisone and colchicine in patients with primary sclerosing cholangitis. *Am J Gastroenterol* 1991;86:57.](#)
201. [Kyokane, K, Ichihara, T, Horisawa, M, et al. Successful treatment of primary sclerosing cholangitis with cyclosporine and corticosteroid. *Hepatogastroenterology* 1994;41:449.](#)

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
202. [Lindor, KD, Jorgensen, RA, Anderson, ML, et al. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: A pilot study. Am J Gastroenterol 1996;91:511.](#)
203. [Schramm, C, Schirmacher, P, Helmreich-Becker, I, et al. Combined therapy with azathioprine, prednisolone, and ursodiol in patients with primary sclerosing cholangitis. Ann Intern Med 1999;131:943.](#)
204. [van Hoogstraten, HJ, Vleggaar, FP, Boland, GJ, et al. Budesonide or prednisone in combination with ursodeoxycholic acid in primary sclerosing cholangitis: a randomized double-blind pilot study. Belgian-Dutch PSC Study Group. Am J Gastroenterol 2000;95:2015.](#)
205. Sterling RK, Salvatori JJ, Luketic VA, et al. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis. Aliment Pharmacol Ther 2004;20:943-9.
206. [Davies, YK, Cox, KM, Abdullah, BA, et al. Long-term treatment of primary sclerosing cholangitis in children with oral vancomycin: an immunomodulating antibiotic. J Pediatr Gastroenterol Nutr 2008;47:61.](#)
207. [Silveira, MG, Torok, NJ, Gossard, AA, et al. Minocycline in the treatment of patients with primary sclerosing cholangitis: results of a pilot study. Am J Gastroenterol 2009;104:83.](#)
208. [Farkkila, M, Karvonen, AL, Nurmi, H, et al. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial. Hepatology 2004;40:1379.](#)

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

For Peer Review

Table1: Trials of UDCA in PSC

Reference	Type of study	No. of patients	Dose of UDCA	Duration (months)	Outcomes
Chazouillères et al, 1990 [44]	Prospective	15	750-1250 mg	6	Improved liver function and symptoms.
O'Brien et al, 1991 [45]	Open-label	12	10 mg/kg	30	Improved liver function and symptoms.
Beuers et al, 1992 [43]	Double-blind, placebo-controlled	6	13-15 mg/kg	12	Improved liver function and histology. No effect on symptoms.
Lo et al, 1992 [176]	Double-blind placebo controlled	23	10 mg/kg	24	Improved liver function. No effect on symptoms or histology
Stiehl et al, 1994 [177]	Double-blind, placebo-controlled	20	750 mg	12-48	Improved liver function and histology. No effect on symptoms.
De Maria et al, 1996 [178]	Double-blind placebo controlled	59	600 mg	24	No improvement in liver function.
Lindor et al, 1997 [47]	Double-blind, placebo-controlled	105	13-15 mg/kg	34	Improved liver function. No effect on histology and symptoms.
Van Hoogstraten et al, 1998 [179]	Double-blind	48	10 mg/kg	24	Improved liver function. No effect on symptoms.
Mitchell et al, 2001 [49]	Double-blind, placebo-controlled	26	20-25 mg/kg	24	Improved liver function, histology and cholangiography. No effect on symptoms. No survival benefit.
Harnois et al, 2001 [180]	Open label	30	25-30 mg/kg	12	Improved liver function and survival compared with Mayo risk score.
Okolicsanyi et al, 2003 [181]	Open-label, placebo-controlled	86	8-13 mg/kg	120	Improved liver function and symptoms. No effect on histology.
Olsson et al, 2005 [50]	multi-centre randomised Double-blind, placebo-controlled	219	17-23 mg/kg	60	Improved liver function. Non-significant trend towards increased survival. No effect on symptoms.
Cullen et al, 2008 [51]	Pilot dose range study	30	10 mg/kg 20 mg/kg 30 mg/kg/	24	Improved projected survival with low and standard dose. Significantly improved projected survival with high dose.
Lindor et al, 2009 [48]	multi-centre Double-blind, placebo-controlled	150	28-30mg/kg	60	Improved liver function. No improvement in symptoms or histology. Discontinued early (6yrs): significantly risk of death, need for liver transplant or development of varicies.

Table 2: Trials of immunosuppressants, antifibrinolytics, biological therapy and other agents in monotherapy in PSC

Reference	Type of study	No. of patients	Therapy	Duration	Outcomes
Angulo et al, 2000 [182]	Pilot study	21	Budesonide 9mg od oral	1 year	Improvement liver biochemistry. No effect on Mayo risk score. Significant worsening of osteoporosis (femoral neck and lumbar spine).
Knox et al, 1991 [183]	Open study	10 (pre cirrhotic)	Methotrexate 15mg/week oral, pulsed	12 months	Improved liver function and histology
Knox et al, 1994 [184]	Double-blind placebo controlled trial	24	Methotrexate 15mg/week oral, pulsed	24 months	Improvement in serum ALP. No effect on other liver biochemistry, liver histology, cholangiograms or outcome.
Sandborn et al, 1993 [185]	Controlled trial	35	Cyclosporine 4mg/kg/day oral	2 year FU	No improvement in biochemistry or histology. Controls associated UC.
Van Theil et al, 1995 [186]	Open study	10	Tacrolimus bd oral	12 months	Improvement liver biochemistry
Olsson et al, 1995 [187]	Double blind placebo controlled randomised study	84	Colchicine 1mg/day oral	36 months	No effect on symptoms, liver biochemistry, histology or survival.
LaRusso et al, 1988 [188]	Randomized,, double-blind trial	70	Penicillamine 250mg tds oral	36 months	No effect on symptoms, liver function, histology, or survival. Side effects in 21% -discontinued drug
Bharucha et al, 2000 [189]	Open pilot study	20 patients	Pentoxifylline 400 mg qds oral	1 year	No effect on symptoms or liver function tests
Duchini et al, 2000 [190]	Open label pilot trial	4	Cladribine oral	6 months (24 month follow-up)	Improvement in histology. No effect on symptoms, liver biochemistry, cholangiograms.
Angulo et al, 2002 [191]	Pilot study	24	Pirfenidone 2400mg oral	12 months	No effect in liver biochemistry, histology, cholangiogram, Mayo risk score.
Angulo et al, 1999 [192]	Open study	8	Nicotine 6 mg qds oral	12 months	No effect on liver function. Frequent side effects.
Vleggaar et al, 2001 [193]	Double blind placebo-controlled randomised cross-over study	12	Nicotine 15mg/day transdermal patch	2 months	No effect on symptoms or liver biochemistry.
Epstein et al, 2004 [194]	Pilot study	10	Etanercept 25mg twice/week sc t	6-12 months	Minimal improvement in pruritis only. No effect on liver biochemistry or cholangiograms.
Talwalkar et al, 2005 [195]	Pilot study	30	Mycophenolate mofetil 1-3g oral	12 months	Improved ALP. No effect on other liver biochemistry or Mayo risk score
Talwalker et al, 2007 [196]	Open labelled phase II study	16	Tacrolimus 0.05mg/kg bd oral	1 year	Improvement ALP. Adverse side effects.
Hommers et al, 2008 [197]	Double blind placebo controlled study	10	Infliximab 5mg/kg (weeks 0, 2, 6, 12, 18, 24) intravenous	26 weeks, prematurely halted	no significant differences in liver biochemistry at week 18 or histological parameters at week 26
Angulo et al, 2008 [198]	Pilot study	30	Silymarin 140mg tds oral	12 months	Improvement in liver biochemistry (except bilirubin).
Mizuno et al, 2010 [199]	Non-controlled study	7 patients	Bezafibrate 400mg/day oral	8-27 months	Improved liver biochemistry. No effect on symptoms. Not assess progression or survival.

Table 3: Combination therapy in PSC

Reference	Type of study	No. of patients	Therapy	Duration	Outcomes
Lindor et al, 1991 [200]	Historical controlled trial	12	Prednisolone 10mg/day and colchicine 0.6mg bd	24 months	No benefit in liver biochemistry or histology. Trend towards improved survival.
Kyokane et al, 1994 [201]	Case report	1 ?definite PSC	Methylprednisolone and cyclosporine	unknown	Improved cholangiogram and pancreatography
Lindor et al, 1996 [202]	Pilot study	19	Methotrexate 0.25mg/kg/week and UDCA 13-15mg/kg/day	24 months	No effect on symptoms or liver biochemistry. Increased risks of toxicity with MTX.
Schramm et al, 1999 [203]	Case series	15	Azathioprine 1.5mg/kg/day and prednisolone 1mg/kg/day (taper to 10mg/day) and UDCA 500-750mg/day	41 months (median)	Improved liver biochemistry and histology. Adverse events in 2 patients leading to withdrawal of the drugs.
Van Hoogstraten et al, 2000 [204]	Double blind randomised pilot trial	18	UDCA 12mg/kg/day with no response at 5 months, add prednisone 10mg or budesonide 3mg or 9mg/day	2 month	No benefit of combining budesonide with UDCA. Minimal short-term improvements in liver biochemistry and symptoms with prednisolone and UDCA.
Stirling et al, 2004 [205]	Randomised controlled pilot study	25	UDCA 13-15mg/kg/day and Mycophenolatemofetil 1000mg bd	24 months	No effect on liver biochemistry, histology, cholangiograms.

Table 4: Antibiotics trials in PSC

Reference	Type of study	No. of patients	Therapy	Duration	Outcomes
Davies et al, 2008 [207]	Pilot study	14 children	Vancomycin oral	2 months	Improvement in liver biochemistry and symptoms. Best results in those without cirrhosis.
Silveria et al, 2009 [208]	Pilot study	16	Minocycline 100mg bd oral	12 months	Significant improvement in liver biochemistry and Mayo risk score.
Farkkila et al, 2004 [209]	Randomized controlled trial	80	Metronidazole with or without UDCA	36 months	Improved serum ALP and new Mayo risk score with combination therapy. No effect on cholangiogram or disease progression.

For Peer Review

Table 5: Extrahepatic complications of PSC

Pruritis	<ul style="list-style-type: none"> Exclude bile duct obstruction from a dominant stricture Exclude UDCA causing a paradoxical worsening of pruritis <u>1st line</u>: Cholestyramine or other resins. Effective in 80 to 90% of patients, despite a limited evidence base¹²⁶⁻¹²⁸ <u>2nd line</u>: Rifampicin. Although drug-induced hepatitis, liver dysfunction and discolouration of bodily fluids limit its use¹²⁹⁻¹³⁰ <u>3rd line</u>: Naltrexone; Sertraline; Ondansetron¹³⁰⁻¹³⁴. Etanercept has also been shown to relieve pruritis in a study without this as its primary aim¹³⁵ Intractable pruritis is an indication for liver transplantation.
Fatigue	<ul style="list-style-type: none"> Exclude other causes including hypothyroidism, anaemia, diabetes, depression, and medication Management is supportive: <ol style="list-style-type: none"> Minimise factors exacerbating autonomic dysfunction and sleep disturbance¹²³ Provide psychological support to develop coping strategies¹²³ <ul style="list-style-type: none"> Modafinil: can be effective in patients with primary biliary cirrhosis (PBC) who have fatigue associated with prominent daytime somnolence, but has not been studied in PSC¹³⁶ Liver transplantation is not indicated for fatigue alone
Malabsorption	<ul style="list-style-type: none"> Prolonged cholestasis can lead to the malabsorption of fat and fat-soluble vitamins. Supplement vitamins A, E and K enterally in the presence of steatorrhoea or laboratory evidence of malabsorption Parenteral vitamin K in overt cholestasis and in the context of bleeding, prior to invasive procedures such as sphincterotomy and/or stent insertion at ERCP¹²³
Metabolic bone disease	<ul style="list-style-type: none"> Increased risk of hepatic osteodystrophy in advanced liver disease and/or overt cholestasis. Incidence between 4 and 10%. Assess risk for osteoporosis in all PSC patients <p><u>Higher risk</u>: longer duration of IBD, more advanced liver disease and post-transplantation, especially within the first 3 months¹³⁷⁻¹³⁸</p> <p><u>Established population risk factors</u> for osteoporosis provide additional risk that outweighs cholestasis-related risk</p> <ul style="list-style-type: none"> Bone mineral density assessment (DEXA) at presentation DEXA re-screening between 1 and 5 years depending on outcome, degree of cholestasis and individual risk factors^{123,137} Measures to prevent and treat hepatic osteodystrophy (based on evidence from PBC) including calcium and vitamin D supplements; bisphosphonates; hormone replacement therapy in post-menopausal females¹³⁹⁻¹⁴⁰

Table 6: Indications for Liver Transplantation in PSC

Indications similar to other end stage liver disease	<ul style="list-style-type: none">• Chronic liver failure• Complications of portal hypertension• Impaired quality of life
Special indications in PSC despite a low priority MELD (less than or equal to 17) or UKELD (less than or equal to 49) score	<ul style="list-style-type: none">• Intractable pruritis• Recurrent or refractory bacterial cholangitis• Severe extra-hepatic biliary obstruction that precludes operative repair• Uncontrolled peristomal variceal bleeding• Limited stage peripheral or hilar cholangiocarcinoma (in the context of a clinical trial with careful selection of patients and neo-adjuvant therapy)^{116,166}. The merits of theses cases are decided on an individual basis.